Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer by Generali, D et al.
14 December 2021
AperTO - Archivio Istituzionale Open Access dell'Università di Torino
Original Citation:
Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response





(Article begins on next page)
Anyone can freely access the full text of works made available as "Open Access". Works made available under a
Creative Commons license can be used according to the terms and conditions of said license. Use of all other works
requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.
Availability:
This is the author's manuscript
This version is available http://hdl.handle.net/2318/57792 since
Phosphorylated ER, HIF-1, and MAPK Signaling As
Predictors of Primary Endocrine Treatment Response and
Resistance in Patients With Breast Cancer
Daniele Generali, Francesca M. Buffa, Alfredo Berruti, Maria P. Brizzi, Leticia Campo, Simone Bonardi,
Alessandra Bersiga, Giovanni Allevi, Manuela Milani, Sergio Aguggini, Mauro Papotti, Luigi Dogliotti,
Alberto Bottini, Adrian L. Harris, and Stephen B. Fox
From the Molecular Oncology Laborato-
ries, Weatherall Institute of Molecular
Medicine; Nuffield Department of Clini-
cal Laboratory Sciences, John Radcliffe
Hospital, University of Oxford, Oxford,
United Kingdom; Unità di Patologia
Mammaria – Breast Cancer Unit and
Anatomia Patologica, Azienda Instituti
Ospitalieri di Cremona, Cremona;
Anatomia Patologica; Oncologia
Medica, Dipartimento di Scienze
Cliniche e Biologiche, Università di
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A B S T R A C T
Purpose
We aimed to identify signaling pathways involved in the response and resistance to aromatase
inhibitor therapy in patients with breast cancer.
Patients and Methods
One hundred fourteen women with T2-4 N0-1, estrogen receptor (ER) –positive tumors were
randomly assigned to neoadjuvant letrozole or letrozole plus metronomic cyclophosphamide.
Twenty-four tumor proteins involved in apoptosis, cell survival, hypoxia, angiogenesis, growth
factor, and hormone signaling were assessed by immunohistochemistry in pretreatment samples
(eg, caspase 3, phospho- mammalian target of rapamycin, hypoxia-inducible factor 1 [HIF-1],
vascular endothelial growth factor, mitogen-activated protein kinase [MAPK], phosphorylated
epidermal growth factor receptor, phosphorylated ER [pER]). A multivariate generalized linear
regression approach was applied using a penalized least-square minimization to perform
variable selection and regularization. Ten-fold cross-validation and iterative leave-one-out were
employed to validate and test the model, respectively. Tumor size, nodal status, age, tumor grade,
histological type, and treatment were included in the analysis.
Results
Ninety-one patients (81%) attained a disease response, 48 achieved a complete clinical response
(43%) whereas 22 did not respond (19%). Increased pER and decreased p44/42 MAPK were
significant factors for complete response to treatment in all leave-one-out iterations. Increased
p44/42 MAPK and HIF-1 were significant factors for treatment resistance in all leave-one-out
iterations. There was no significant interaction between these variables and treatment.
Conclusion
Activated ER form was an independent factor for sensitivity to chemoendocrine treatment,
whereas HIF-1 and p44/42 MAPK were independent factors for resistance. Although further
confirmatory analyses are needed, these findings have clear potential implications for future
strategies in the management of clinical trials with aromatase inhibitors in the breast cancer.
J Clin Oncol 27:227-234. © 2008 by American Society of Clinical Oncology
INTRODUCTION
Aromatase inhibitors (AIs) have increased response
rates compared with tamoxifen1-3 in breast cancer
(BC) but like tamoxifen a significant number of pa-
tients treated with AIs fail to attain a disease re-
sponse. Research into the mechanism of endocrine
responsiveness and resistance in BC has revealed
that growth factor pathways and oncogenes in-
volved in cell signaling bypass the effects of
endocrine treatment.4 There are data to sup-
port central roles for the epidermal growth factor
receptor (EGFR) and HER2 in the development of
such resistance.5,6 It is likely that they induce an
autocrine loop leading to an induction of key regu-
lators of cell proliferation and cell survival,6,7 such
as mitogen activated protein kinase (MAPK),8-10
phoshatidylinositol 3-kinase (PI3K), and its down-
stream effector the mammalian target of rapamy-
cin (mTOR).11
Primary systemic therapy with AIs is com-
monly used in postmenopausal women with estro-
gen receptor (ER) –positive tumors.12,13 In this
light, we considered that primary systemic therapy
with the AI letrozole could be used to identify the
signaling pathways responsible for endocrine sensi-
tivity and resistance that might be targeted with
combination strategies to individualize treatment in
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the future. We have used such an approach to evaluate the activation
status of cell signaling pathways potentially related to endocrine re-
sponse in a series of BC specimens obtained before letrozole-based
therapy.14 Our aims were to test which markers were correlated with
response to endocrine treatment and to assess which were associ-
ated with resistance. The studied pathways include phospho-EGFR
(pEGFR) and HER2 growth factor receptors, MAPK (p38 and p44/
p42) pathways,15,16 metabolic pathways (PI3K, phospho-AKT and
phospho-mTOR),7 apoptosis and proliferation (caspase 3, p53, bcl2,
bNIP3, cyclin D1, Ki67),17 the hypoxia-related proteins (hypoxia-
inducible factor 1 [HIF-1], CAIX, prolyl hydroxylase (PHD) 1,
PHD2, and PHD3),18-20 angiogenesis (vascular endothelial growth
factor [VEGF], cyclooxygenase [COX-2],21,22 immunosuppressive
tumor infiltration by regulatory T cells [TReg] ),
23 and ER signaling
(ER, phospho-ER, ER, progesterone receptor [PgR], and fork-
head box protein [FOXP1]24-26).
PATIENTS AND METHODS
Patients and Treatment Management
This was a single center, randomized, phase II trial in which patients were
assigned to one of two treatment arms on a 1:1 ratio (letrozole alone [LET arm]
or letrozole and metronomic chemotherapy with cyclophosphamide [LET-
CYC arm] given continuously for 6 months until definitive surgery) as previ-
ously described.27 Between November 2000 and January 2004, elderly women
(age  70 years) or women unfit for chemotherapy between 65 and 70 years
old with T2-4 N0-1 and ER-positive BC were considered eligible.27 The study
was approved by the local ethical committee. Written informed consent was
obtained from all patients before random assignment.
Treatment Evaluation
On first presentation, an incisional biopsy (0.5 to 0.8 cm3) was per-
formed. Tumor size and response was assessed by the same specialist, accord-
ing to the WHO criteria28 by the clinical measurement of the changes in the
product of the two largest diameters recorded in two successive evaluations.
Tumor progression (PD) was defined as an increase of at least 25% in tumor
size; stable disease (SD) as an increase of less than 25%, or a reduction of less
than 50%; partial response (PR) as a tumor shrinkage greater than 50%; and
complete response (CR)30 as the complete disappearance of all clinical signs of
disease. Pathologic complete response (pCR) was defined as the absence of
neoplastic cells in the breast and in the axillary lymph nodes after histology.
Surgery (quadrantectomy or modified radical mastectomy in association with
full axillary node dissection) was planned after clinical reassessment. All pa-
tients subjected to quadrantectomy underwent irradiation of the residual
breast (60 Gy delivered over 6 weeks).
Histopathologic Grade and Immunohistochemistry
Immunohistochemical evaluation for routine markers was performed
on paraffin-embedded tumor samples of whole tumor sections obtained at
diagnosis for bcl2, p53, HER2, ER, PgR, and Ki67 as described elsewhere.31
The antibodies, sources, and protocols used for the other markers are
referenced in Table 1.32-38 Immunohistochemistry for all these markers was
performed on 5- sections of tissue microarray containing two 1-mm diam-
eter cores taken from selected morphologically representative tumor regions
from the incisional biopsy. Quality control was assessed on each block by
hematoxylin and eosin staining. The Envision HRP kit (Dako; Cam-
bridgeshire, United Kingdom) system was used for subsequent visualization.
Staining was assessed in the nucleus for HIF1-, FOXP3, Ki67, ER,
pER, ER, PgR, and p53, nucleus and cytoplasm for PHD1, PHD2, PHD3,
FOXP1, phospho-AKT (pAKT), BNIP3, phospho-p38 MAPK, and phospho-
p44/42; membrane for CAIX, pEGFR, and HER2; cytoplasm for bcl-2, VEGF,
phospho-mTOR, PI3K, Cyclin D1, COX-2, and caspase-3. All sections had a
negative control slide (no primary antibody) of an adjacent section to preclude
nonspecific staining. Positive controls included breast carcinomas known to
exhibit high levels of each marker. A single pathologist, blinded to patient
outcome and to the origin of the samples, used a semi-quantitative method.
Intensity was semi-quantitively assessed: 0 (no staining), 1 (weak staining), 2
(moderate staining), or 3 (strong staining) for HIF1-, ER, p53, PHD1,
PHD2, PHD3, phospho-AKT (pAKT), phospho-p38, MAPK, and phospho-
p44/42, CAIX, pEGFR, VEGF, phospho-mTOR, PI3K, Cyclin D1, COX-2.
The cutoff for FOXP3, FOXP1, PgR, ER, HER2, bcl-2, Ki67, and BNIP3 was
as previously reported.26,27,39,40 For pER, the Allred score was used as a
continuous variable.
Some scores of the markers were missing due to insufficient tumor or
unsatisfactory staining. The approach to missing cases was to exclude cases
where the value of the covariate under study was missing in the univariate
analysis and to exclude cases when 1 or more covariates were missing in the
multivariate analysis.
Statistical Methodology
A regression approach was chosen, the elastic-net method,36 that ad-
dresses the problem of variable selection and regularization in multivariate
analyses by using least-square penalization. This method is particularly pow-
erful with respect to standard linear regression when the size of the study (ie,
the number of cases) is small with respect to the number of covariates. It
applies a combination of the L1 and L2 penalty; that is, it performs least-square
minimization while enforcing a constrain on a combination term including
the sum of the absolute values of the regression coefficients and the sum of
their squares (for details, see Zou and Hastie36). This enables efficient variable
selection and encourages a grouping effect, where strongly correlated predic-
tors tend to stay in or out of the model together. A cross-validation approach
was used to build and validate the model as described in Zou and Hastie.36
Specifically, the L1 and L2 parameters in the penalized least-square were tuned
using the following steps: select a grid of values for the L2 parameter ranging
from 0 to 100, for each of these values tune the L1 parameter using 10-fold
cross-validation, finally choose the value of the L2 parameter which provides
the smallest cross-validation error.
Table 1. List of Antibodies Used for the Immunohistochemical Markers
Marker Clone
pER (serine 118)32 16J4
Cyclin D132 DCS6
pmTOR (Ser2448) 33 49F9
HIF-120 ESEE 122
COX-234
p38 MAPK (Thr180/Tyr182)19,35 12F8










Carbonic anhydrase IX37 M75
Caspase-338 84,803
Estrogen receptor beta34 ER
pEGFR32
Abbreviations: pER, phosphorylated estrogen receptor; pmTOR, phosphory-
lated mammalian target of rapamycin; HIF-1, hypoxia-inducible factor 1;
COX, cyclooxygenase; MAPK, mitogen-activated protein kinase; PI3 kinase,
phoshatidylinositol 3-kinase; VEGF, vascular endothelial growth factor; PHD,
prolyl hydroxylase; FOXP, forkhead box protein; BNIP, BCL2/adenovirus E1B
19kDa interacting protein 3; pEGFR, phosphorylated epidermal growth factor
receptor.
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The markers introduced in the model are described in Table 2 where
median, mean, and 95% quantiles are provided. The categorization of the
markers was based on the variables as described earlier. The clinical variables
introduced in the model were tumor size (0 if T  2, 1 if T  2), nodal status
(negative v positive), age, tumor grade, histological type (1  lobular, 2  duc-
tal), and treatment. All scores and clinical variables were standardized before
being introduced in the model by applying location and scale transformation
as described by Zou and Hastie.36
Markers responsible for endocrine response were studied by contrasting
all responders (ie, patients with PR and CR) with nonresponders (NR; ie,
patients with SD and PD).29,30 To further define markers responsible for
chemoendocrine sensitivity, CR was also compared with PR and NR com-
bined.
An iterative leave-one-out approach was used to test the model. At each
step, one case (ie, a single patient) was left out from the analysis, a fit of the
model was produced for the remaining cases using 10-fold cross-validation
and a treatment response prediction was made for the left-out case. This
allowed testing of the models’ ability to predict treatment response, specificity
and sensitivity, and respective area under the receiver operator characteristic
(ROC) curve, were estimated using these predictions. The ROC analysis was
done using the nonparametric option for estimation of the SE of the area
under the curve in SPSS version 15 (SPSS, Chicago, IL); the cross-
validation and leave-one-out analyses were implemented in R 2.5.1 (http://
cran.r-project.org) and the R package elasticnet 1.0 to 3 was used to
perform elastic-net regression.36
RESULTS
One hundred fourteen patients were enrolled, 57 were randomly
assigned to receive 6 months of primary LET and 57 to LET-CYC.
Patient characteristics are outlined in Table 3.
Clinical Response to Treatment
One hundred thirteen patients were evaluated for disease re-
sponse; one patient was not evaluated due to discontinuation of treat-
ment. Ninety-one of 113 patients (80.5%) attained a disease response:
41 (73.2%) of 56 in LET arm and 50 (87.7%) of 57 in LET-CYC arm.
Clinical CR was obtained in 48 patients (42.5%), 23 (41.1%) in LET
arm, and 25 (43.8%) in LET-CYC arm, respectively.
To study markers involved in chemoendocrine response we
compared any responders (ie, PR and CR, 91 [79.8%] v the NR, 22
[19.3%]). Furthermore, to determine markers responsible for che-
moendocrine sensitivity, we compared the CR, 48 patients (42.1%)
versus PR or NR, 65 patients (57%). Mosaic plots (Fig 1) and immu-
nohistochemistry (Fig 2) are shown for the significant factors associ-
ated with response to chemoendocrine treatment.
Factors Associated With Endocrine Sensitivity (CR)
The elastic-net reduced model for sensitivity included nuclear
expression of pER, which was significantly positively correlated with
endocrine sensitivity in all leave-one-out iterations, and cytoplasmic
expression of p44/42 MAPK, which showed significant negative cor-
relation with CR in all iterations (Figs 3A and 3B). pEGFR was signif-
icant in 43 of 62 (69%) of the fits; where increased membrane
pEGFR corresponded with a lower CR. When present, pEGFR
grouped with p44/42 MAPK expression (Fig 3C). None of these fac-
tors showed significant interaction with treatment in any of the leave-
one-out iterations. All other variables were significant in less than 50%
of the leave-one-out models or never significant (Fig 3C). The test of
the model on the cases which were left out from the model building
(one at each iteration) gave an area under the ROC curve of 0.5 with
95% confidence limits of 0.35 to 0.65; thus, the null hypothesis of
ROC  0.5 (random prediction) could not be rejected.
Factors Associated With Endocrine Response
(nonresponders v responders)
p44/42 MAPK cytoplasmic expression intensity was the only
prognostic factor that was significant in the reduced model of endo-
crine resistance in all leave-one-out iterations showing a consistent
Table 2. Molecular Markers Considered in This Study
Molecular Marker Localization Median Mean 95% CI
Tissue microarray
pER intensity Nucleus 3.0 3.6 0.0 to 8.0
Cyclin D1 intensity Cytoplasm 1.0 1.0 0.0 to 3.0
Phospho-mTOR intensity Cytoplasm 2.0 1.8 0.0 to 3.0
HIF-1 intensity Nucleus 1.0 1.2 0.0 to 3.0
COX-2 intensity Cytoplasm 2.0 1.6 0.0 to 3.0
p38 MAPK intensity Cytoplasm 1.0 0.9 0.0 to 2.0
p38 MAPK intensity Nucleus 1.0 1.2 0.0 to 3.0
p44/42 MAPK intensity Cytoplasm 1.0 1.1 0.0 to 2.8
p44/42 MAPK intensity Nucleus 1.0 1.1 0.0 to 3.0
pEGFR intensity Membrane 1.0 1.3 0.0 to 3.0
PI3K intensity Cytoplasm 2.0 2.2 1.0 to 3.0
pAKT intensity Cytoplasm 2.0 2.0 0.0 to 3.0
VEGF intensity Cytoplasm 2.0 2.2 1.0 to 3.0
Routine markers (whole
slide staining)
ER 310.0 301.6 164.0 to 410.0
PgR 170.0 145.2 0.0 to 343.0
bcl2 100.0 83.2 0.0 to 100.0
NOTE. Markers considered in the analysis had  20% of missing values (ie,
the marker was assessed in at least or more than 80% of the patients) or
 20% positivity in sample staining (ie, the marker stained positive in at least
20% of the samples).
Abbreviations: pER, phosphorylated estrogen receptor; mTOR, mamma-
lian target of rapamycin; HIF-1, hypoxia-inducible factor 1; COX, cyclo-
oxygenase; MAPK, mitogen-activated protein kinase; pEGFR, phosphorylated
epidermal growth factor receptor; PI3 kinase, phoshatidylinositol 3-kinase;
VEGF, vascular endothelial growth factor; ER, estrogen receptor; PgR, pro-
gesterone receptor.





No. % No. %
Median age, years 79 75
Range 64-89 62-94
TNM
T2 42 73.7 44 77.2
T3-4 15 26.3 13 22.8
N0 35 61.4 41 71.9
N1 22 38.6 16 28.1
Primary histology
Ductal carcinoma 44 77.2 47 82.5
Lobular carcinoma 13 22.8 10 17.5
Grade
2 22 38.6 22 39.3
3 35 61.4 34 60.7
Not assessable — 1
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negative correlation with clinical response (Fig 3D). Nuclear HIF-1
was also significant in all leave-one-out fits and grouped with cytoplas-
mic p44/42 MAPK showing a similar negative correlation with re-
sponse (Fig 3E and 3F). Neither of these factors showed significant
interaction with treatment in any of the leave-one-out iterations.
The test of the model on the cases which were left out from the
model building (one at each iteration) gave an area under the ROC
curve of 0.69 with 95% confidence limits of 0.53 to 0.85; thus, the null
hypothesis of ROC  0.5 (random prediction) could be rejected
with P  .037.
Analysis of Post-Treatment Ki67 and Post-Treatment
T-Stage As Markers of Relapse-Free Survival
Due to the relatively short follow-up analysis of relapse-free sur-
vival was possible and thus post-treatment ki67 expression and high
post-treatment stage that have been shown to correlate with relapse-
free survival in previous studies34,41 have been used as surrogates.
Post-treatment Ki67 showed a significant inverse correlation with
clinical response (NR v PR v CR; 2 10.85, P .001; Appendix Table
A1, online only). A full multivariate regression analysis of the mark-
ers was not performed as the distribution of post-treatment Ki67 is
highly skewed (Appendix Fig A1, online only). However, the three
main significant factors for treatment response, p44/42 MAPK, HIF-
1, and pER, showed a significant positive (P  .001), positive
(P  .001), and negative (P  .004) association , respectively, with
high post-treatment stage (Moses test for extreme tendencies). Post-
treatment T-stage was also significantly correlated with clinical re-
sponse (2  14.41; P  .006), with a significantly lower number of
CR present in stages higher than 1 after treatment with respect to NR
or PR (Appendix Table A2, online only). As with Ki67 expression, a
full covariate analysis of the markers was not performed as the distri-
bution of post-treatment stage is highly skewed (Appendix Fig A2,
online only). However, the three main significant factors for treatment
response, p44/42 MAPK, HIF-1, and pER, showed a significant a
positive (P  .001), positive (P  .001), and negative (P  .005)
association, respectively, with high post-treatment stage (Moses test
for extreme tendencies).
DISCUSSION
The neoadjuvant model provides a valuable approach for testing bio-
logic hypotheses and to study the predictive role of signaling pathways.
We have used such a model to measure the basal expression of differ-
ent putative markers of the kinase signaling and hypoxia regulated
pathways involved in endocrine responsiveness/resistance that may
predict clinical response.
To analyze these data, we have employed a generalized linear
regression method that addresses the problem of dimensionality re-
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Fig 1. Mosaic plots of the factors that
were consistently associated with endo-
crine response. (A) A mosaic plot of
p44/42 MAPK cytoplasmic expression and
pER nuclear expression with treatment
response; gray corresponds to complete
response (CR), gold to partial response
(PR), and blue to no response (NR; ie, PD
and SD). (B) A mosaic plot of p44/42
MAPK cytoplasmic expression and pER
nuclear expression with CR (gray) or
PR/NR (light gray). A mosaic plot of p44/42
MAPK cytoplasmic expression and HIF-1
nuclear expression with any response (ie,
CR and PR [gray]) or NR [light gray]).
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This analysis identified nuclear pER as a significant indepen-
dent factor for sensitivity to chemoendocrine treatment. Moreover,
providing further support to the potential of nuclear pER as a marker
of response, nuclear pER was significantly negatively associated with
high post-treatment ki67 expression and with high post-treatment
stage, both of which have been shown to correlate with clinical out-
come in previous studies.34,41 The identification of nuclear pER as
related to CR is in keeping with the findings of Murphy et al25 who
reported phosphorylated serine118 ER expression correlated with an
improved disease outcome in patients with BC treated with hormone
therapy.42 The role of phosphorylated serine118 ER being a marker of
response to antiestrogen therapy is further supported by its enhanced
expression that develops during the hypersensitive phase that occurs
after long-term estrogen deprivation in ER-positive BC cells.9,43
Thus, since the phosphorylated serine118 ER may be a more precise
marker of endocrine-based treatment response (unlike ER, ER,
and PgR in our multiple logistic regression) it should be further eval-
uated for determining its use in endocrine therapy.44 Indeed, this is an
important issue since conventional ER as assessed by immunohisto-
chemistry predicts response to hormone therapy in only 36% to 55%
of patients, although this can be improved with the use of PgR.2,3
Nevertheless, although this study showed that the model of endocrine
sensitivity was valid during cross-validation it lacked generality when
tested on patients who did not contribute to the model building. Thus,
a larger series of patients is required to refine and confirm the endo-
crine sensitivity model.
Emerging evidence suggests that other adaptive changes occur
during prolonged endocrine therapy with crosstalk between growth
factor pathways and ER.10,16,37 Thus, EGFR, HER2, insulin growth
factor, and transforming growth factor family members result in
phosphorylation of serine 118 (and 167) of ER through MAPK and
other intermediates including PKC and AKT.5,33,35 However, it is
presently unclear whether this ligand-independent activation of ER
contributes to resistance. Although EGFR through MAPK may result
in serine118 ER phosphorylation, we observed no association be-
tween MAPK and pER suggesting that MAPK may preferentially
phosphorylate other targets that contribute to antiestrogen resistance,
independent of ER signaling. One such alternative mechanism is con-
stitutive activation of MAPK pathway which alters p27 phosphoryla-
tion leading to a reduction of cdk2 inhibitory activity.32
Although letrozole is able to reduce estrogen levels by 90% in
breast tumors,38 tumors may acquire resistance and thus an ability to
grow in the presence of AIs. In vivo models suggest that while letrozole
initially prevents tumor growth, after long exposure it induces an
activation of several growth factor cascades, such as MAPK pathways,
that might be responsible for reducing/inhibiting AI activity.45 In this
study, p44/42MAPK and HIF-1 were found to be significantly associ-
ated with endocrine resistance and were significantly positively associated
with high post-treatment stage. These data together with a significant
positive correlation between these two factors provide strong evidence for
a central role for p44/42 MAPK in endocrine resistance.
Although growth factor signaling mediates a significant propor-
tion of this resistance, the results indicate that HIF-1 may also be
responsible. The hypoxic microenvironment favors malignant pro-
gression of cancer (reviewed by Harris)46 and hypoxia, via HIF-1,
may promote estrogen-independent growth and a more aggressive BC
phenotype.18 Indeed, ER expression is lower in HIF-1 positive than
in negative BC18 and hypoxia has been shown to reduce the expression
of ER and the inhibitory effects of antiestrogens in vitro.18,47 Tumor
hypoxia also activates the MAPK pathway48 which in turn phosphor-
ylates HIF-1,49 suggesting hypoxia and growth factor signals may
synergize to augment the HIF-1 mediated response. The upregula-
tion of pathways involved in glycolysis, angiogenesis, pH regulation,
and downregulation of ER lead to endocrine resistance.14,50 Our
results suggest that a HIF-1 and MAPK may define patients resistant
to AIs and thus identify patients who may benefit from other thera-
peutic strategies including MAPK and HIF inhibitors for which several







Fig 2. Expression of markers of resis-
tance (hypoxia-inducible factor 1, p44/
p42, mitogen-activated protein kinase)
and responsiveness (phosphorylated es-
trogen receptor ) in a tumor with no
clinical response11 and a tumor with a
complete clinical response.30
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pathway to activate bioreductive drugs, such as tirapazamine, that inhibit
DNA repair under hypoxic conditions52 and has been shown to have an
antiangiogeniceffectaswell asdirectantitumoractivity.53 Itwouldalsobe
of interest to examine the role of these pathways in response to bevaci-
zumab in patients with BC treated with endocrine therapy.
In conclusion, to our knowledge, this is the first report in a clinical
datasetdemonstratingtheroleofcytoplasmicp44/42MAPKandnuclear
HIF-1 in endocrine resistance and of nuclear pER in endocrine
responsiveness in patients receiving letrozole-based treatment. Fur-
thermore, no significant interaction with treatment was observed for
these factors, suggesting that this profile might be only related to the AI
effect. Nevertheless, an additional effect for cyclophosphamide cannot
be discounted and confirmatory studies will be needed. Thus, the
results support the development of new treatment strategies based on
the combination of AI with signal transduction inhibitors as a means
to prevent endocrine resistance with signal transduction inhibitor(s)
targeting mainly MAPK (but also HIF1) administered with an AI
being more effective than using an AI alone.8,47 They also stress the
heterogeneity of baseline signaling pathways and suggest that trials
might benefit from selecting patients with combinations of AIs.
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Fig 3. Main effect estimate for significant factors in the reduced model of endocrine response. The complete distribution of the main effect estimate in the leave-one-out
iterations is shown for the factors that were consistently significant in the reduced model of (A, B, C) endocrine sensitivity and (D, E, F) response, respectively. The heatmaps
on the right panels (C and F) display the leave-one-out model results at each iteration (y-axis) for factors (x-axis) that were significant in at least 5% of the iterations. In these
heatmaps, double-clustering is performed just for the visual purpose of grouping together similar model results and similar main effects; standard correlation was used. Red
indicates positive association; blue indicates negative association; and white indicates no significant association.
Generali et al
232 © 2008 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Copyright © 2009 by the American Society of Clinical Oncology. All rights reserved. 
October 19, 2009 from 130.192.124.122. 
Information downloaded from jco.ascopubs.org and provided by Universita Studi Di Torino - Biblioteca Polo Clinico on
Collection and assembly of data: Daniele G. Generali, Francesca M.
Buffa, Alfredo Berruti, Maria P. Brizzi, Simone Bonardi, Giovanni Allevi,
Manuela Milani, Mauro Papotti
Data analysis and interpretation: Francesca M. Buffa, Adrian L. Harris
Manuscript writing: Daniele G. Generali, Francesca M. Buffa, Alfredo
Berruti, Adrian L. Harris, Stephen B. Fox
Final approval of manuscript: Daniele G. Generali, Francesca M. Buffa,
Luigi Dogliotti, Adrian L. Harris, Stephen B. Fox
REFERENCES
1. Smith IE, Dowsett M: Aromatase inhibitors in
breast cancer. N Engl J Med 348:2431-2442, 2003
2. Eiermann W, Paepke S, Appfelstaedt J, et al:
Preoperative treatment of postmenopausal breast
cancer patients with letrozole: A randomized double-
blind multicenter study. Ann Oncol 12:1527-1532,
2001
3. Smith IE, Dowsett M, Ebbs SR, et al: Neoad-
juvant treatment of postmenopausal breast cancer
with anastrozole, tamoxifen, or both in combination:
The Immediate Preoperative Anastrozole, Tamox-
ifen, or Combined with Tamoxifen (IMPACT) multi-
center double-blind randomized trial. J Clin Oncol
23:5108-5116, 2005
4. Nicholson RI, McClelland RA, Robertson JF,
et al: Involvement of steroid hormone and growth
factor cross-talk in endocrine response in breast
cancer. Endocr Relat Cancer 6:373-387, 1999
5. Knowlden JM, Hutcheson IR, Jones HE, et al:
Elevated levels of epidermal growth factor receptor/
c-erbB2 heterodimers mediate an autocrine growth
regulatory pathway in tamoxifen-resistant MCF-7
cells. Endocrinology 144:1032-1044, 2003
6. Kurokawa H, Arteaga CL: ErbB (HER) recep-
tors can abrogate antiestrogen action in human
breast cancer by multiple signaling mechanisms.
Clin Cancer Res 9:511S-15S, 2003
7. Campbell RA, Bhat-Nakshatri P, Patel NM, et
al: Phosphatidylinositol 3-kinase/AKT-mediated acti-
vation of estrogen receptor alpha: A new model for
anti-estrogen resistance. J Biol Chem 276:9817-
9824, 2001
8. Kurokawa H, Lenferink AE, Simpson JF, et al:
Inhibition of HER2/neu (erbB-2) and mitogen-
activated protein kinases enhances tamoxifen action
against HER2-overexpressing, tamoxifen-resistant
breast cancer cells. Cancer Res 60:5887-5894, 2000
9. Martin LA, Farmer I, Johnston SR, et al:
Enhanced estrogen receptor (ER) alpha, ERBB2, and
MAPK signal transduction pathways operate during
the adaptation of MCF-7 cells to long term estrogen
deprivation. J Biol Chem 278:30458-30468, 2003
10. Nicholson RI, Hutcheson IR, Hiscox SE, et
al: Growth factor signaling and resistance to se-
lective oestrogen receptor modulators and pure
anti-oestrogens: The use of anti-growth factor
therapies to treat or delay endocrine resistance in
breast cancer. Endocr Relat Cancer 12:S29-S36,
2005 (suppl 1)
11. deGraffenried LA, Friedrichs WE, Russell DH,
et al: Inhibition of mTOR activity restores tamoxifen
response in breast cancer cells with aberrant Akt
Activity. Clin Cancer Res 10:8059-8067, 2004
12. Abrial C, Mouret-Reynier MA, Cure H, et al:
Neoadjuvant endocrine therapy in breast cancer.
Breast 15:9-19, 2005
13. Freedman OC, Verma S, Clemons MJ: Using
aromatase inhibitors in the neoadjuvant setting:
Evolution or revolution? Cancer Treat Rev 31:1-17,
2005
14. Generali D, Berruti A, Brizzi MP, et al:
Hypoxia-inducible factor-1alpha expression predicts
a poor response to primary chemoendocrine therapy
and disease-free survival in primary human breast
cancer. Clin Cancer Res 12:4562-4568, 2006
15. Schiff R, Massarweh SA, Shou J, et al: Ad-
vanced concepts in estrogen receptor biology and
breast cancer endocrine resistance: Implicated role
of growth factor signaling and estrogen receptor
coregulators. Cancer Chemother Pharmacol 56:10-
20, 2005 (suppl 1)
16. Osborne CK, Shou J, Massarweh S, et al:
Crosstalk between estrogen receptor and growth
factor receptor pathways as a cause for endocrine
therapy resistance in breast cancer. Clin Cancer Res
11:865s-870s, 2005
17. Thiantanawat A, Long BJ, Brodie AM: Signal-
ing pathways of apoptosis activated by aromatase
inhibitors and antiestrogens. Cancer Res 63:8037-
8050, 2003
18. Kurebayashi J, Otsuki T, Moriya T, et al:
Hypoxia reduces hormone responsiveness of hu-
man breast cancer cells. Jpn J Cancer Res 92:1093-
1101, 2001
19. Chia SK, Wykoff CC, Watson PH, et al: Prog-
nostic significance of a novel hypoxia-regulated
marker, carbonic anhydrase IX, in invasive breast
carcinoma. J Clin Oncol 19:3660-3668, 2001
20. Appelhoff RJ, Tian YM, Raval RR, et al: Differ-
ential function of the prolyl hydroxylases PHD1,
PHD2, and PHD3 in the regulation of hypoxia-
inducible factor. J Biol Chem 279:38458-38465,
2004
21. Coradini D, Pellizzaro C, Speranza A, et al:
Hypoxia and estrogen receptor profile influence the
responsiveness of human breast cancer cells to
estradiol and antiestrogens. Cell Mol Life Sci 61:76-
82, 2004
22. Manders P, Beex LV, Tjan-Heijnen VC, et al:
Vascular endothelial growth factor levels do not
predict efficacy of systemic adjuvant treatment as
assessed in 1127 breast cancer patients. Int J Oncol
25:511-517, 2004
23. Polanczyk MJ, Carson BD, Subramanian S, et
al: Cutting edge: Estrogen drives expansion of the
CD4CD25 regulatory T cell compartment. J Im-
munol 173:2227-2230, 2004
24. Iwase H, Zhang Z, Omoto Y, et al: Clinical
significance of the expression of estrogen receptors
alpha and beta for endocrine therapy of breast
cancer. Cancer Chemother Pharmacol 52:S34-S38,
2003 (suppl 1)
25. Murphy LC, Niu Y, Snell L, et al: Phospho-
serine-118 estrogen receptor-alpha expression is
associated with better disease outcome in women
treated with tamoxifen. Clin Cancer Res 10:5902-
5906, 2004
26. Fox SB, Brown P, Han C, et al: Expression of
the forkhead transcription factor FOXP1 is associ-
ated with estrogen receptor alpha and improved
survival in primary human breast carcinomas. Clin
Cancer Res 10:3521-3527, 2004
27. Bottini A, Generali D, Brizzi MP, et al: Ran-
domized phase II trial of letrozole and letrozole plus
low-dose metronomic oral cyclophosphamide as
primary systemic treatment in elderly breast cancer
patients. J Clin Oncol 24:3623-3628, 2006
28. World Health Organization: World Health
Organization, WHO handbook for reporting results
of cancer treatment. Geneva, Switzerland, World
Health Organization, 1978
29. Roncador G, Brown PJ, Maestre L, et al:
Analysis of FOXP3 protein expression in human
CD4CD25 regulatory T cells at the single-cell
level. Eur J Immunol 35:1681-1691, 2005
30. Glode LM, Barqawi A, Crighton F, et al: Metro-
nomic therapy with cyclophosphamide and dexameth-
asone for prostate carcinoma. Cancer 98:1643-1648,
2003
31. Bottini A, Berruti A, Bersiga A, et al: p53 but
not bcl-2 immunostaining is predictive of poor clini-
cal complete response to primary chemotherapy in
breast cancer patients. Clin Cancer Res 6:2751-
2758, 2000
32. Donovan JC, Milic A, Slingerland JM: Consti-
tutive MEK/MAPK activation leads to p27(Kip1) de-
regulation and antiestrogen resistance in human
breast cancer cells. J Biol Chem 276:40888-40895,
2001
33. Gee JM, Robertson JF, Gutteridge E, et al:
Epidermal growth factor receptor/HER2/insulin-like
growth factor receptor signalling and oestrogen
receptor activity in clinical breast cancer. Endocr
Relat Cancer 12:S99-S111, 2005 (suppl 1)
34. Dowsett M, Smith IE, Ebbs SR, et al: Short-
term changes in Ki-67 during neoadjuvant treatment
of primary breast cancer with anastrozole or tamox-
ifen alone or combined correlate with recurrence-
free survival. Clin Cancer Res 11:951s-958s, 2005
35. Nicholson RI, Hutcheson IR, Knowlden JM, et
al: Nonendocrine pathways and endocrine resis-
tance: Observations with antiestrogens and signal
transduction inhibitors in combination. Clin Cancer
Res 10:346S-54S, 2004
36. Zou H, Hastie T: Regularization and variable
selection via the elastic net. J R Statist Soc B
67:301-320, 2005
37. Shou J, Massarweh S, Osborne CK, et al:
Mechanisms of tamoxifen resistance: Increased
estrogen receptor-HER2/neu cross-talk in ER/HER2-
positive breast cancer. J Natl Cancer Inst 96:926-
935, 2004
38. Long BJ, Jelovac D, Thiantanawat A, et al: The
effect of second-line antiestrogen therapy on breast
tumor growth after first-line treatment with the
aromatase inhibitor letrozole: Long-term studies us-
ing the intratumoral aromatase postmenopausal
breast cancer model. Clin Cancer Res 8:2378-2388,
2002
39. Bates GJ, Fox SB, Han C, et al: Quantification
of regulatory T cells enables the identification of
high-risk breast cancer patients and those at risk of
late relapse. J Clin Oncol 24:5373-5380, 2006
40. Tan EY, Campo L, Han C, et al: Cytoplasmic
location of factor-inhibiting hypoxia-inducible factor
is associated with an enhanced hypoxic response
and a shorter survival in invasive breast cancer.
Breast Cancer Res 9:R89, 2007
41. Carey LA, Metzger R, Dees EC, et al: Ameri-
can Joint Committee on Cancer tumor-node-
metastasis stage after neoadjuvant chemotherapy
and breast cancer outcome. J Natl Cancer Inst
97:1137-1142, 2005
42. Murphy L, Cherlet T, Adeyinka A, et al:
Phospho-serine-118 estrogen receptor-alpha detec-
tion in human breast tumors in vivo. Clin Cancer Res
10:1354-1359, 2004
43. Chan CM, Martin LA, Johnston SR, et al:
Molecular changes associated with the acquisition
Molecular Profile of Endocrine Response and Resistance in Breast Cancer
www.jco.org © 2008 by American Society of Clinical Oncology 233
Copyright © 2009 by the American Society of Clinical Oncology. All rights reserved. 
October 19, 2009 from 130.192.124.122. 
Information downloaded from jco.ascopubs.org and provided by Universita Studi Di Torino - Biblioteca Polo Clinico on
of oestrogen hypersensitivity in MCF-7 breast can-
cer cells on long-term oestrogen deprivation. J Ste-
roid Biochem Mol Biol 81:333-341, 2002
44. Osborne CK: Steroid hormone receptors in
breast cancer management. Breast Cancer Res
Treat 51:227-238, 1998
45. Jelovac D, Sabnis G, Long BJ, et al: Activation
of mitogen-activated protein kinase in xenografts
and cells during prolonged treatment with aro-
matase inhibitor letrozole. Cancer Res 65:5380-
5389, 2005
46. Harris AL: Hypoxia: A key regulatory factor in
tumour growth. Nat Rev Cancer 2:38-47, 2002
47. Kronblad A, Hedenfalk I, Nilsson E, et al:
ERK1/2 inhibition increases antiestrogen treatment
efficacy by interfering with hypoxia-induced down-
regulation of ERalpha: A combination therapy poten-
tially targeting hypoxic and dormant tumor cells.
Oncogene 24:6835-6841, 2005
48. Minet E, Arnould T, Michel G, et al: ERK
activation upon hypoxia: Involvement in HIF-1 acti-
vation. FEBS Lett 468:53-58, 2000
49. Richard DE, Berra E, Gothie E, et al: P42/p44
mitogen-activated protein kinases phosphorylate
hypoxia-inducible factor 1alpha (HIF-1alpha) and en-
hance the transcriptional activity of HIF-1. J Biol
Chem 274:32631-32637, 1999
50. Generali D, Fox SB, Berruti A, et al: Role of
carbonic anhydrase IX expression in prediction of
the efficacy and outcome of primary epirubicin/
tamoxifen therapy for breast cancer. Endocr Relat
Cancer 13:921-930, 2006
51. Semenza GL: Targeting HIF-1 for cancer ther-
apy. Nat Rev Cancer 3:721-732, 2003
52. Rischin D, Peters L, Fisher R, et al: Tira-
pazamine, cisplatin, and radiation versus fluoroura-
cil, cisplatin, and radiation in patients with locally
advanced head and neck cancer: A randomized phase II
trial of the Trans-Tasman Radiation Oncology Group
(TROG 98.02). J Clin Oncol 23:79-87, 2005
53. Nagasawa H, Yamashita M, Mikamo N, et al:
Design, synthesis and biological activities of antian-
giogenic hypoxic cytotoxin, triazine-N-oxide deriva-




Aromatase inhibitors: Used in treating breast cancer in
postmenopausal women, aromatase inhibitors inhibit the conver-
sion of androgens to estrogens by the enzyme aromatase, thus
depriving the tumor of estrogenic signals. Because of decreased
production of estrogen, estrogen receptors, which are important
in the progression of breast cancer, cannot be activated.
HIF (hypoxia-inducible factor): HIF is a transcriptional
factor that regulates the adaptive responses of mammalian cells to
low oxygen (hypoxia: oxygen concentration below normal physio-
logical limits in a specific tissue. Under these circumstances). It is
composed of HIF-1, which is upregulated in conditions of hypoxia,
and HIF-1 (or aryl hydrocarbon receptor nuclear translocators),
which is expressed constitutively. Dimerization of HIF-1 with
HIF-1 leads to transcription of genes such as VEGF and PDGF.
VEGF (vascular endothelial growth factor): VEGF is a
cytokine that mediates numerous functions of endothelial cells in-
cluding proliferation, migration, invasion, survival, and permeabil-
ity. VEGF is also known as vascular permeability factor. VEGF
naturally occurs as a glycoprotein and is critical for angiogenesis.
Many tumors overexpress VEGF, which correlates to poor progno-
sis. VEGF-A, -B, -C, -D, and -E are members of the larger family of
VEGF-related proteins.
Pathologic complete response (pathCR): The absence of
any residual tumor cells in a histologic evaluation of a tumor speci-
men is defined as a complete pathologic response.
Metronomic chemotherapy: A schedule of chemotherapy
given at lower doses to allow more frequent administration without
the induction of myelosuppression seen with maximum tolerated
dose (MTD) regimens. This type of regimen is also called antiangio-
genic scheduling due to the fact that slowly proliferating (angio-
genic) endothelial cells are more efficiently targeted by metronomic
chemotherapy than by MTD regimens, resulting in inhibition of
tumor growth due to insufficient neovascularization.
mTOR: The mammalian target of rapamycin belongs to a protein
complex (along with raptor and G  L) that is used by cells to sense
nutrients in the environment. mTOR is a serine/threonine kinase
that is activated by Akt and regulates protein synthesis on the basis of
nutrient availability. It was discovered when rapamycin, a drug used
in transplantation, was shown to block cell growth presumably by
blocking the action of mTOR.
MAPK (mitogen-activated protein kinase): MAPKs are a fam-
ily of enzymes that form an integrated network influencing cellular
functions such as differentiation, proliferation, and cell death. These
cytoplasmic proteins modulate the activities of other intracellular
proteins by adding phosphate groups to their serine/threonine
amino acids.
EGFR (epidermal growth factor receptor): Also known as
HER-1, EGFR belongs to a family of receptors (HER-2, HER-3,
HER-4 are other members of the family) and binds to the EGF,
TGF-, and other related proteins, leading to the generation of pro-
liferative and survival signals within the cell. It also belongs to the
larger family of tyrosine kinase receptors and is generally overex-
pressed in several solid tumors of epithelial origin.
ER (estrogen receptor): Belonging to the class of nuclear re-
ceptors, estrogen receptors are ligand-activated nuclear proteins
present in many breast cancer cells that are important in the progres-
sion of hormone-dependent cancers. After binding, the receptor-
ligand complex activates gene transcription. There are two types of
estrogen receptors ( and ). ER is one of the most important pro-
teins controlling breast cancer function. ER is present in much
lower levels in breast cancer and its function is uncertain. Estrogen-
receptor status guides therapeutic decisions in breast cancer.
Regulatory T cells (known as suppressor T cells): are a
specialized subpopulation of T cells that act to suppress activation of
the immune system and thereby maintain immune system homeosta-
sis and tolerance to self-antigens. This is an important “self-check”
built into the immune system so that responses do not go haywire.
Regulatory T cells come in many forms, including those that express
the CD8 transmembrane glycoprotein (CD8 T cells), those that
express CD4, CD25 and Foxp3 (CD4CD25 regulatory T cells or
“Tregs”) and other T cell types that have suppressive function. These
cells are involved in closing down immune responses after they have suc-
cessfully tackled invading organisms and also in keeping in check immune
responses that may potentially attack one’s own tissues (autoimmunity).
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